Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note

Adma Biologics (ADMA) closed at $18.59 in the latest trading session, marking a +1.81% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.13% for the day. On the other hand, the Dow registered a loss of 0.39%, and the technology-centric Nasdaq increased by 0.15%. Coming into today, shares of the infectious disease drug developer had gained 2.13% in the past month. In that same time, the Medical sector lost 0.96%, while the S&P 500 gained 3.39%. Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure. In that report, analysts expect Adma Biologics to post earnings of $0.14 per share. This would mark year-over-year growth of 7.69%. Simultaneously, our latest consensus estimate expects the revenue to be $121.1 million, showing a 12.98% escalation compared to the year-ago quarter. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $0.61 per share and revenue of $505.8 million. These totals would mark changes of +24.49% and +18.61%, respectively, from last year. Investors should also pay attention to any latest changes in analyst estimates for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. At present, Adma Biologics boasts a Zacks Rank of #4 (Sell). Valuation is also important, so investors should note that Adma Biologics has a Forward P/E ratio of 29.93 right now. This expresses a premium compared to the average Forward P/E of 19.79 of its industry. The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 91, placing it within the top 37% of over 250 industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow ADMA in the coming trading sessions, be sure to utilize Zacks.com. #1 Semiconductor Stock to Buy (Not NVDA)The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ADMA Biologics Inc (ADMA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks